{"id":"wpv01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5278228","moleculeType":null,"molecularWeight":"525.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"WPV01 works by inhibiting the SARS-CoV-2 main protease, which is essential for the replication of the virus. This inhibition prevents the virus from replicating and reduces the severity of the disease. WPV01 has shown promise in preclinical studies as a potential treatment for COVID-19.","oneSentence":"WPV01 is a small molecule drug that targets the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:02.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT07080658","phase":"PHASE1","title":"[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants","status":"COMPLETED","sponsor":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","startDate":"2023-07-23","conditions":"COVID-19","enrollment":6},{"nctId":"NCT06205329","phase":"PHASE1","title":"Study of WPV01 in Healthy Subjects","status":"COMPLETED","sponsor":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","startDate":"2022-10-03","conditions":"Healthy Participants","enrollment":108},{"nctId":"NCT06197217","phase":"PHASE3","title":"Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19","status":"COMPLETED","sponsor":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","startDate":"2023-06-14","conditions":"Mild to Moderate COVID-19","enrollment":1350},{"nctId":"NCT05752175","phase":"PHASE2","title":"Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection","status":"COMPLETED","sponsor":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","startDate":"2023-03-10","conditions":"COVID-19 Infection","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"WPV01","genericName":"WPV01","companyName":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","companyId":"westlake-pharmaceuticals-hangzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"WPV01 is a small molecule drug that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}